Recent and current Phase II clinical trials in endometrial cancer: review of the state of art

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30
   PubMed Web of Science ®Google Scholar
• Lindemann K, Vatten LJ, Ellstrom-Engh M, Eskild A. Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study. Br J Cancer 2008;98(9):1582-5
   PubMed Web of Science ®Google Scholar
• Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11(12):1531-43
   PubMed Web of Science ®Google Scholar
• Cook LS, Nelson HE, Stidley CA, et al. Endometrial cancer and a family history of cancer. Gynecol Oncol 2013;130(2):334-9
   PubMed Web of Science ®Google Scholar
• Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi33-8
   PubMed Web of Science ®Google Scholar
• Marchetti C, Pisano C, Mangili G, et al. Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: a multicenter retrospective study. Oncology 2011;81(2):104-12
   PubMed Web of Science ®Google Scholar
• Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31(20):2607-18
   PubMed Web of Science ®Google Scholar
• Folkins AK, Longacre TA. Hereditary gynaecological malignancies: advances in screening and treatment. Histopathology 2013;62(1):2-30
   PubMed Web of Science ®Google Scholar
• Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a “sentinel cancer” for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol 2005;105(3):569-74
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Gallinger S, Tsao MS, et al. Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG). Eur J Cancer 2010;46(8):1365-73
   PubMed Web of Science ®Google Scholar
• Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7(8):606-19
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010;7(4):209-19
   PubMed Web of Science ®Google Scholar
• Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet 1997;17(2):143-4
   PubMed Web of Science ®Google Scholar
• Minaguchi T, Yoshikawa H, Oda K, et al. PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 2001;7(9):2636-42
   PubMed Web of Science ®Google Scholar
• Peiro G, Peiro FM, Ortiz-Martinez F, et al. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment. Hum Pathol 2013;44(2):218-25
   PubMed Web of Science ®Google Scholar
• Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128(1):157-70
   PubMed Web of Science ®Google Scholar
• Gupta A, Yang Q, Pandita RK, et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009;8(14):2198-210
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S105-43
   PubMedGoogle Scholar
• Tangjitgamol S, Manusirivithaya S, Lertbutsayanukul C. Adjuvant therapy for early-stage endometrial cancer: a review. Int J Gynecol Cancer 2007;17(5):949-56
   PubMed Web of Science ®Google Scholar
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105(2):103-4
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24(1):36-44
   PubMed Web of Science ®Google Scholar
• Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46(13):2422-31
   PubMed Web of Science ®Google Scholar
• Geller MA, Ivy JJ, Ghebre R, et al. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer. Gynecol Oncol 2011;121(1):112-17
   PubMed Web of Science ®Google Scholar
• Lupe K, D'Souza DP, Kwon JS, et al. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer. Gynecol Oncol 2009;114(1):94-8
   PubMed Web of Science ®Google Scholar
• Einstein MH, Frimer M, Kuo DY, et al. Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma. Gynecol Oncol 2012;124(1):21-5
   PubMed Web of Science ®Google Scholar
• Scribner DR Jr, Puls LE, Gold MA. A phase II evaluation of docetaxel and carboplatin followed by tumor volume directed pelvic plus or minus paraaortic irradiation for stage III endometrial cancer. Gynecol Oncol 2012;125(2):388-93
   PubMed Web of Science ®Google Scholar
• Jhingran A, Ramondetta LM, Bodurka DC, et al. A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium. Gynecol Oncol 2013;129(2):304-9
   PubMed Web of Science ®Google Scholar
• Narayan K, Rischin D, Quinn M, et al. Adjuvant chemotherapy and chemoradiation following surgery for high-risk endometrial cancer. J Clin Oncol 2010;28(Suppl):abstract 5028
   Google Scholar
• Landrum LM, Nugent EK, Zuna RE, et al. Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors. Gynecol Oncol 2014;132(1):50-4
   PubMed Web of Science ®Google Scholar
• Koensgen D, Belau A, Sehouli J, et al.N-E SGOG. Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase II study of the NOGGO. J Clin Oncol 2011;29(Suppl):abstract 5109
   Google Scholar
• Lewis GC Jr, Slack NH, Mortel R, Bross ID. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 1974;2(2-3):368-76
   PubMedGoogle Scholar
• Macdonald RR, Thorogood J, Mason MK. A randomized trial of progestogens in the primary treatment of endometrial carcinoma. Br J Obstet Gynaecol 1988;95(2):166-74
   PubMedGoogle Scholar
• Vergote I, Kjorstad K, Abeler V, Kolstad P. A randomized trial of adjuvant progestagen in early endometrial cancer. Cancer 1989;64(5):1011-16
   PubMed Web of Science ®Google Scholar
• Bevis K, Kilgore L, Alvarez R, et al. Combination therapy with paclitaxel, carboplatin, and megesterol acetate for advanced-stage and recurrent endometrial carcinoma: a phase II study. J Clin Oncol 2010;28(Suppl):abstract 5093
   Google Scholar
• Bovicelli A, D'Andrilli G, Giordano A, De Iaco P. Conservative treatment of early endometrial cancer. J Cell Physiol 2013;228(6):1154-8
   PubMed Web of Science ®Google Scholar
• Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125(1):263-70
   PubMed Web of Science ®Google Scholar
• Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186(4):651-7
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999;17(6):1736-44
   PubMed Web of Science ®Google Scholar
• Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011;8(5):261-71
   PubMed Web of Science ®Google Scholar
• Tsoref D, Oza AM. Recent advances in systemic therapy for advanced endometrial cancer. Curr Opin Oncol 2011;23(5):494-500
   PubMed Web of Science ®Google Scholar
• Hoskins PJ, Swenerton KD, Pike JA, et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a Phase II study. J Clin Oncol 2001;19(20):4048-53
   PubMed Web of Science ®Google Scholar
• Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007;25(20):2983-90
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004;22(11):2159-66
   PubMed Web of Science ®Google Scholar
• Tait DL, Blessing JA, Hoffman JS, et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011;121(1):118-21
   PubMed Web of Science ®Google Scholar
• Di Legge A, Trivellizzi IN, Moruzzi MC, et al. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer. Int J Gynecol Cancer 2011;21(8):1446-51
   PubMed Web of Science ®Google Scholar
• Miller DS, Blessing JA, Drake RD, et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115(3):443-6
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Lisyanskaya A, Crispens M, et al. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol 2009;114(2):288-92
   PubMed Web of Science ®Google Scholar
• Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009;27(19):3104-8
   PubMed Web of Science ®Google Scholar
• Emons G, Sehouli J, Gorchev G, et al. Phase II study of AEZS-108 (AN-152), a targeted cytotoxic LHRH analog, in patients with LHRH receptor positive endometrial cancer. Protocol AGO-GYN 5, AGO study group, Germany. Eur J Cancer Suppl 2010;8(7):120
   Google Scholar
• Brown J, Smith JA, Ramondetta LM, et al. Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial. Cancer 2010;116(21):4973-9
   PubMed Web of Science ®Google Scholar
• Vandenput I, Vergote I, Neven P, Amant F. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 2012;22(4):617-22
   PubMed Web of Science ®Google Scholar
• Wright JD, Barrena Medel NI, Sehouli J, et al. Contemporary management of endometrial cancer. Lancet 2012;379(9823):1352-60
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007;17(5):964-78
   PubMed Web of Science ®Google Scholar
• Covens AL, Filiaci V, Gersell D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011;120(2):185-8
   PubMed Web of Science ®Google Scholar
• Kokka F, Brockbank E, Oram D, et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010;(12):CD007926
   Google Scholar
• Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001;19(2):364-7
   PubMed Web of Science ®Google Scholar
• Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004;14(4):650-8
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000;78(2):212-16
   PubMed Web of Science ®Google Scholar
• Ramondetta LM, Johnson AJ, Sun CC, et al. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 2009;115(9):1867-74
   PubMed Web of Science ®Google Scholar
• Whitney CW, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(1):4-9
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92(1):10-14
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51(15):3867-73
   PubMed Web of Science ®Google Scholar
• O'Regan RM, Cisneros A, England GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst 1998;90(20):1552-8
   PubMed Web of Science ®Google Scholar
• Emons G, Gunthert A, Thiel FC, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynakologische Onkologie. Gynecol Oncol 2013;129(3):495-9
   PubMed Web of Science ®Google Scholar
• Utsunomiya H, Ito K, Suzuki T, et al. Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 2004;10(17):5850-6
   PubMed Web of Science ®Google Scholar
• Foster PA, Woo LW, Potter BV, et al. The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. Endocrinology 2008;149(8):4035-42
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010;116(23):5415-19
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29(24):3278-85
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer 2013;108(9):1771-7
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer 2013;108(5):1021-6
   PubMed Web of Science ®Google Scholar
• Mackay H, Welch S, Tsao M, et al. Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. J Clin Oncol 2011;29(Suppl):abstract 5013
   Google Scholar
• Oza A, Poveda A, Clamp A, et al. A randomized phase II (RP2) trial of ridaforolimus (R) compared with progestin (P) or chemotheraphy (C) in female adult patients with advanced endometrial carcinoma. J Clin Oncol 2011;29(Suppl):abstract 5009
   Google Scholar
• Stomovitz BM, Brown J, Johnston TA, et al. A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol 2011;29(Suppl):abstract 5012
   Google Scholar
• Fleming GF, Filiaci VL, Hanjani P, Gynecologic Oncology Group. Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248. J Clin Oncol 2011;29(Suppl):abstract 5014
   Google Scholar
• Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(1):22-7
   PubMed Web of Science ®Google Scholar
• Einstein MH, Wenham RM, Morgan R, et al. Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer. J Clin Oncol 2012;30(Suppl):abstract 5025
   Google Scholar
• Myers AP, Broaddus R, Makker V, SU2C Dream Team: PI3K in Women's Cancers. Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer (EC). J Clin Oncol 2013;31(Suppl):abstract 5524
   Google Scholar
• Mackay HJ, Eisenhauer EA, Kamel-Reid S, et al. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer. Cancer 2014;120(4):603-10
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• McMeekin DS, Sill MW, Benbrook D, et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol 2007;105(2):508-16
   PubMed Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011;29(16):2259-65
   PubMed Web of Science ®Google Scholar
• Wright JD, Powell MA, Rader JS, et al. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007;27(5B):3525-8
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;127(3):538-43
   PubMed Web of Science ®Google Scholar
• Correa R, Mackay H, Hirte HW, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia. J Clin Oncol 2010;28(Suppl):abstract 5038
   Google Scholar
• Funahashi Y, Penson RT, Powell MA, et al. Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer. J Clin Oncol 2013;31(Suppl):abstract 5591
   Google Scholar
• Vergote I, Teneriello M, Powell MA, et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 2013;31(Suppl):abstract 5520
   Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009;16(1):8-13
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129(3):486-94
   PubMed Web of Science ®Google Scholar
• Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008;26(26):4319-25
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010;116(1):15-20
   PubMed Web of Science ®Google Scholar
• Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int 2010;2010:162363
   PubMedGoogle Scholar
• Santin AD. Letter to the Editor referring to the manuscript entitled: “Phase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study” recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010). Gynecol Oncol 2010;118(1):95-6; author reply 96-7
   PubMed Web of Science ®Google Scholar
• Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol 2012;127(2):345-50
   PubMed Web of Science ®Google Scholar
• Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Med 2011;9:33
   PubMed Web of Science ®Google Scholar
• Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010;9(5):1092-9
   PubMed Web of Science ®Google Scholar
• Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol 2010;116(1):92-8
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of metformin and the risk of ovarian cancer: a case-control analysis. Gynecol Oncol 2011;123(2):200-4
   PubMed Web of Science ®Google Scholar
• Sadeghi N, Abbruzzese JL, Yeung SC, et al. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18(10):2905-12
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, McTiernan A, Wactawski-Wende J, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012;30(23):2844-52
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008;17(4):921-9
   PubMed Web of Science ®Google Scholar
• Nevadunsky NS, Van Arsdale A, Strickler HD, et al. Metformin use and endometrial cancer survival. Gynecol Oncol 2014;132(1):236-40
   PubMed Web of Science ®Google Scholar
• Ko EM, Walter P, Jackson A, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol 2014;132(2):438-42
   PubMed Web of Science ®Google Scholar
• Schuler KM, Rambally BS, DiFurio MJ, et al. A preoperative window study of metformin for the treatment of endometrial cancer. J Clin Oncol 2013;31(Suppl):abstract 5519
   Google Scholar
• Myers AP. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details. Clin Cancer Res 2013;19(19):5264-74
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28(30):4594-600
   PubMed Web of Science ®Google Scholar
• Goodwin PJ, Pritchard KI. Obesity and hormone therapy in breast cancer: an unfinished puzzle. J Clin Oncol 2010;28(21):3405-7
   PubMed Web of Science ®Google Scholar
• Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 2008;39(1):116-25
   PubMed Web of Science ®Google Scholar
• de Jong RA, Leffers N, Boezen HM, et al. Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 2009;114(1):105-10
   PubMed Web of Science ®Google Scholar
• Booth CM, Tannock IF. Evaluation of treatment benefit: randomized controlled trials and population-based observational research. J Clin Oncol 2013;31(26):3298-9
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol 2013;3:237
   PubMedGoogle Scholar
• Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010;2(53):53ra75
   PubMed Web of Science ®Google Scholar
• Janzen DM, Paik DY, Rosales MA, et al. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo. Mol Cancer Ther 2013;12(12):2917-28
   PubMed Web of Science ®Google Scholar